RE: BioNTech loses skin in the neoantigen game hopes had dimmed for BioNTech’s Roche-partnered personalised neoantigen project autogene cevumeran in first-line melanoma,14 Mar 2025 09:00
We seem to be getting a bit mixed up here. Looking back at history is all well and good but this investment can only be measured in one way (in the now) and that is return on investment. In this regard there is nothing to report which puts the warm fuzzy nostalgic feelings in perspective.
It is time to start looking at Scancell as an investment. Not because I/we have had some sort of epiphany but because it is at that stage where there is no other question.